Drug Profile
Research programme: paediatric film formulations - Lupin Pharmaceuticals
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Lupin Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Attention-deficit-hyperactivity-disorder in USA (PO)
- 06 Oct 2016 Lupin Pharmaceuticals in-licenses PharmFilm® technology from MonoSol Rx
- 06 Oct 2016 Early research in Attention-deficit hyperactivity disorder in USA (PO) before October 2016